Fig. 3: Prophylactic effects of Tri-M1R-01 against VACV infection via intranasal administration in mice.
From: Identification of neutralizing nanobodies protecting against poxvirus infection
a Experimental design: Balb/c mice were administered intranasally (IN) with 10 mg/kg of Tri-M1R-01 or an anti-SARS-CoV-2 Nb (NB10) as a control. Thirty minutes after the administration, mice were IN challenged with a lethal dose of VACV and survival was monitored. Five days post-infection, lungs, spleens, and blood were collected for subsequent analysis. b Time course of body weight changes in Balb/c mice (n = 5 per group). c Survival curves of mice (n = 5 per group). d Spleen-to-body weight ratio (mg/g), n = 5, bars indicate the mean ± SEM. e, f Virus titers in the blood (e) and lungs (f) were determined. Bars represent the mean ± SEM of mice (n = 4). g The Hematoxylin and Eosin (H&E) staining of lung sections from each group. Scale bars, 300 µm. The data presented in this figure are derived from one of two independent experiments, with 8–10 mice per group. A one-way ANOVA test was employed for significance analysis. Statistical significance was shown as *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
